SCHEMBL2980266

SCHEMBL2980266

CO[C@H](O[C]=O)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.39
THRB P10828 1/20 0.38
CYP3A4 P08684 1/20 0.36
EPHX1 P07099 1/20 0.34
ACP3 P15309 1/20 0.34
IDO1 P14902 1/20 0.34
TDO2 P48775 1/20 0.34
ALDH1A1 P00352 4/20 0.33
LMNA P02545 2/20 0.33
GAA P10253 2/20 0.33
ADRA2A P08913 1/20 0.33
ADRA2C P18825 1/20 0.33
HIF1A Q16665 1/20 0.33
KDM4E B2RXH2 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL120227 1.00 KMT2A (0.39) KMT2ATHRBCYP3A4EPHX1ACP3
SCHEMBL27822368 0.80 CA1 (0.42) KMT2AACP3ALDH1A1GAATSHR
SCHEMBL6003200 0.80 ADRA2A (0.35) KMT2ATHRBALDH1A1LMNAADRA2A
SCHEMBL26689 0.79 KMT2A (0.44) KMT2ATHRBEPHX1IDO1TDO2
SCHEMBL27775233 0.79 THRB (0.38) KMT2ATHRBCYP3A4EPHX1IDO1
SCHEMBL7292294 0.79 L3MBTL1 (0.41) KMT2ALMNAL3MBTL1
SCHEMBL28489517 0.78 AOC3 (0.44) CYP3A4ALDH1A1L3MBTL1
SCHEMBL7644220 0.78 SLC6A4 (0.36) KMT2ALMNAADRA2AADRA2CTSHR
SCHEMBL8698025 0.77 LMNA (0.37) KMT2AALDH1A1LMNAADRA2AADRA2C
SCHEMBL1129750 0.77 CYP3A4 (0.49) KMT2ACYP3A4ALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772432-B2 Amidobenzamide derivatives which are useful as cytokine inhibitors ASTRAZENECA AB (SE) 2010-08-10 US disclosed
US-20090062351-A1 Benzoyl amino pyridyl carboxylic acid derivatives useful as glucokinase (glk) activators ASTRAZENECA AB (SE) 2009-03-05 US disclosed
US-20080234273-A1 Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes ASTRAZENECA AB (SE) 2008-09-25 US disclosed
US-20050038081-A1 Amidobenzamide derivatives which are useful as cytokine inhibitors ASTRAZENECA 2005-02-17 US disclosed
EP-1482927-A1 METHOD OF TREATING OSTEOARTHRITIS Warner-Lambert Company LLC (US) 2004-12-08 EP disclosed
EP-1469841-A1 ALPHA 2 DELTA LIGANDS TO TREAT TINNITUS WARNER-LAMBERT COMPANY (US) 2004-10-27 EP disclosed
WO-2003074048-A1 METHOD OF TREATING OSTEOARTHRITIS WARNER-LAMBERT COMPANY LLC (US) 2003-09-12 WO disclosed
WO-2003063845-A1 ALPHA 2 DELTA LIGANDS TO TREAT TINNITUS WARNER-LAMBERT COMPANY LLC (US) 2003-08-07 WO disclosed
US-5378690-A Treatment of angiotensin induced hypertension SANKYO COMPANY, LIMITED (JP) 1995-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038081-A1 Amidobenzamide derivatives which are useful as cytokine inhibitors IL6, IL6ST, IL2 KMT2A 1554/4885THRB 806/4885CYP3A4 360/4885
US-20080234273-A1 Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes GCK, GCKR, HK1 KMT2A 1920/4885THRB 1369/4885CYP3A4 397/4885
US-20090062351-A1 Benzoyl amino pyridyl carboxylic acid derivatives useful as glucokinase (glk) activators GCK, GCKR, GALK1 KMT2A 1379/4885THRB 1326/4885CYP3A4 844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.